A Retrospective Study to Evaluate the Clinical Outcome According to Treatment in Atypical Hemolytic Uremic Syndrome (aHUS) Patients in South Korea
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs Eculizumab (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome
- Focus Therapeutic Use
- Sponsors Handok Inc
- 27 Jan 2025 Status changed to completed.
- 07 Jun 2022 New trial record